Abstract
Rheumatoid Arthritis (RA) is a chronic progressive inflammatory joint disorder that affects 0.5% â € “ 1% of the general population. This review article discusses cardiovascular manifestations of rheumatoid arthritis, pathogenesis of these manifestations, and therapy. This disease not only affects the joints, but it also involves other organ systems. The majority of these patients suffer significant morbidity and mortality from cardiovascular disease. Cardiovascular manifestations of RA include predilection for accelerated atherosclerosis and endothelial dysfunction resulting in coronary artery disease (CAD), stroke, congestive heart failure, and peripheral arterial disease. Some studies have shown that the risk of developing CAD in RA patients is the same as for patients with diabetes mellitus. These patients should be treated with aggressive medical therapy such as disease modifying antirheumatic drugs, tumor necrosis factor alpha inhibitors, and corticosteroids and with appropriate control of risk factors such as smoking, dyslipidemia, hypertension, and obesity. Other manifestations include pericarditis, myocarditis, and vasculitis.
Keywords: Rheumatoid arthritis, cardiovascular disease, coronary artery disease, inflammatory joint disorder, morbidity, mortality, atherosclerosis, endothelial dysfunction, stroke, corticosteroids
Current Pharmaceutical Design
Title: Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Volume: 18 Issue: 11
Author(s): William M. Mellana, Wilbert S. Aronow, Chandrasekar Palaniswamy and Sahil Khera
Affiliation:
Keywords: Rheumatoid arthritis, cardiovascular disease, coronary artery disease, inflammatory joint disorder, morbidity, mortality, atherosclerosis, endothelial dysfunction, stroke, corticosteroids
Abstract: Rheumatoid Arthritis (RA) is a chronic progressive inflammatory joint disorder that affects 0.5% â € “ 1% of the general population. This review article discusses cardiovascular manifestations of rheumatoid arthritis, pathogenesis of these manifestations, and therapy. This disease not only affects the joints, but it also involves other organ systems. The majority of these patients suffer significant morbidity and mortality from cardiovascular disease. Cardiovascular manifestations of RA include predilection for accelerated atherosclerosis and endothelial dysfunction resulting in coronary artery disease (CAD), stroke, congestive heart failure, and peripheral arterial disease. Some studies have shown that the risk of developing CAD in RA patients is the same as for patients with diabetes mellitus. These patients should be treated with aggressive medical therapy such as disease modifying antirheumatic drugs, tumor necrosis factor alpha inhibitors, and corticosteroids and with appropriate control of risk factors such as smoking, dyslipidemia, hypertension, and obesity. Other manifestations include pericarditis, myocarditis, and vasculitis.
Export Options
About this article
Cite this article as:
M. Mellana William, S. Aronow Wilbert, Palaniswamy Chandrasekar and Khera Sahil, Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy, Current Pharmaceutical Design 2012; 18 (11) . https://dx.doi.org/10.2174/138161212799504795
DOI https://dx.doi.org/10.2174/138161212799504795 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Viral Infection - A Cure for Type 1 Diabetes?
Current Medicinal Chemistry Cardioprotective Effects and <i>in-silico</i> Antioxidant Mechanism of L-Ergothioneine in Experimental Type-2 Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Obesity in the Cardiovascular Continuum
Current Clinical Pharmacology Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress
Current Cardiology Reviews Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design AMP-Activated Protein Kinase (AMPK): Regulation of Metabolic Gene Expression
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Oxidative stress and myocarditis
Current Pharmaceutical Design Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Value of Real Time Three Dimensional Transesophageal Echocardiography in General Cardiology Practice
Recent Patents on Medical Imaging MicroRNA-34a Promotes Cardiomyocyte Apoptosis Post Myocardial Infarction Through Down-regulating Aldehyde Dehydrogenase 2
Current Pharmaceutical Design Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design